Biodel, Inc. (Nasdaq: BIOD) announced today that its chief executive
officer, Dr. Sol Steiner, will present results from the company’s two
Phase 3 studies with VIAject® ultra-rapid-acting recombinant human
insulin in a platform presentation at the 3rd International
Conference on Advanced Technologies and Treatments for Diabetes in
Basel, Switzerland, on Friday, February 12, 2010, at 1pm central
European time. The presentation, entitled “Clinical Findings for
Patients Treated with VIAject®, An Ultra-Rapid Acting Formulation of
Recombinant Human Insulin,” will review and update key data from the
VIAject® clinical development program. Dr. Steiner’s presentation will
be available on the company’s website, www.Biodel.com,
after the presentation.
“Clinical Findings for
Patients Treated with VIAject®, An Ultra-Rapid Acting Formulation of
Recombinant Human Insulin”
Intensive blood pressure treatment reduces cardiovascular risk in people with Type 2 diabetes